Composition

ABSTRACT

Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.

FIELD OF THE INVENTION

This invention is directed to pharmaceutical compositions, dosage forms,and dosing regimens, in particular to certain discrete and particulardosages of 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one,which may be useful in the treatment of various disorders, for examplethe treatment of allergic diseases and other inflammatory conditions,for example allergic rhinitis and allergic asthma.

BACKGROUND OF THE INVENTION

International Patent Application, publication number WO 2010/018133(SmithKline Beecham Corporation), relates to certain purine derivativesdisclosed as inducers of human interferon which may be useful in thetreatment of various disorders, for example the treatment of allergicdiseases and other inflammatory conditions, for example allergicrhinitis and allergic asthma. One particular purine derivative disclosedin WO 2010/018133 is6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one.Co-pending International Patent Application, application numberPCT/EP2009/051830 (GlaxoSmithKline LLC), discloses a maleate salt of6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one.

SUMMARY OF THE INVENTION

This invention is directed to pharmaceutical dosage forms, means forproviding such pharmaceutical dosage forms, pharmaceutical compositions,and dosing regimens for6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one(‘Compound (I)’)

which may be useful in the treatment of various disorders, for examplethe treatment of allergic diseases and other inflammatory conditions,for example allergic rhinitis and allergic asthma.

DETAILED DESCRIPTION OF THE INVENTION

International Patent Application, publication number WO 2010/018133(SmithKline Beecham Corporation), relates to certain purine derivativesdisclosed as inducers of human interferon which may be useful in thetreatment of various disorders, for example the treatment of allergicdiseases and other inflammatory conditions, for example allergicrhinitis and allergic asthma. One particular purine derivative disclosedin WO 2010/018133 is6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one.Co-pending International Patent Application, application numberPCT/EP2009/051830 (GlaxoSmithKline LLC), discloses a maleate salt of6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one(hereinafter ‘Compound (I)’).

It is now surprisingly indicated that certain discrete and particulardosages of Compound (I) may be useful in the treatment of variousdisorders, for example the treatment of allergic diseases and otherinflammatory conditions, for example allergic rhinitis and allergicasthma.

Accordingly, in a first aspect, there is provided a pharmaceuticaldosage form comprising Compound (I), or a pharmaceutically acceptablesalt thereof, and means for providing a metered-dose of Compound (I), ora pharmaceutically acceptable salt thereof.

A suitable pharmaceutical dosage form provides 0.5 nanogramme to 20000nanogrammes of Compound (I) per actuation of the metering means, forexample 0.5 nanogramme to 5 microgrammes, for example 1 nanogramme to 5microgrammes, for example 0.5 nanogramme to 999 nanogrammes, for example1 nanogramme to 999 nanogrammes.

In a further aspect, there is provided a pharmaceutical compositioncomprising Compound (I) or a pharmaceutically acceptable salt thereof,characterised in that the pharmaceutical composition is suitable for usewith metering means.

In a further aspect, there is provided a method of treatment of allergicdiseases and other inflammatory conditions, for example allergicrhinitis and allergic asthma, which method comprises the administrationof Compound (I), or a pharmaceutically acceptable salt thereof, in anamount equivalent to 0.5 nanogramme to 40000 nanogrammes of Compound(I), for example 1 nanogramme to 20000 nanogrammes, for example 2nanogrammes to 20000 nanogrammes, for example 1 nanogramme to 4000nanogrammes, for example 2 nanogrammes to 4000 nanogrammes, for example1 nanogramme to 999 nanogrammes, for example 2 nanogrammes to 999nanogrammes, to a human in need thereof.

There is also provided Compound (I) or a pharmaceutically acceptablesalt thereof, for use in treatment of allergic diseases and otherinflammatory conditions, for example allergic rhinitis and allergicasthma, characterised in that 0.5 nanogramme to 40000 nanogrammes, forexample 1 nanogramme to 20000 nanogrammes, for example 2 nanogrammes to20000 nanogrammes, for example 1 nanogramme to 4000 nanogrammes, forexample 2 nanogrammes to 4000 nanogrammes, for example 1 nanogramme to999 nanogrammes, for example 2 nanogrammes to 999 nanogrammes, ofCompound (I) is administered to a human in need thereof.

Examples of doses of Compound (I) are 0.5 nanogramme, 1 nanogramme, 2nanogrammes, 5 nanogrammes, 10 nanogrammes, 20 nanogrammes, 30nanogrammes, 40 nanogrammes, 50 nanogrammes, 60 nanogrammes, 70nanogrammes, 80 nanogrammes, 90 nanogrammes, and 100 nanogrammes ofCompound (I).

Compounds of formula (I) and pharmaceutically acceptable salts thereofmay be administered at any appropriate frequency, for example 1-7 timesper week, for example once per week.

A desired dose of Compound (I) may be provided by one or two actuationsof the metering means as appropriate given the amount of thepharmaceutical composition dispensed per actuation of the meteringmeans, and the concentration of the pharmaceutical composition beingdispensed. For example, two actuations of the metering means may beused.

Suitable pharmaceutically acceptable salts of Compound (I) include thosedescribed in WO 2010/018133 and a maleate salt. In one aspect, thepharmaceutically acceptable salt is a maleate salt, in particular the1:1 maleate salt.

The pharmaceutical compositions comprising Compound (I), or apharmaceutically acceptable salt thereof, are suitably administered bythe intranasal or inhaled route.

Compositions and Dosage Forms

Compositions for intranasal administration include aqueous compositionsadministered to the nose by drops or by pressurised pump. Suitablecompositions contain water as the diluent or carrier for this purpose.Compositions for administration to the lung or nose may contain one ormore excipients, for example one or more suspending agents, one or morepreservatives, one or more surfactants, one or more tonicity adjustingagents, one or more co-solvents, and may include components to controlthe pH of the composition, for example a buffer system. Further, thecompositions may contain other excipients such as antioxidants, forexample sodium metabisulphite, and taste-masking agents. Compositionsmay also be administered to the nose or other regions of the respiratorytract by nebulisation.

Intranasal compositions may permit the compound(s) of formula (I) or (a)pharmaceutically acceptable salt(s) thereof to be delivered to all areasof the nasal cavities (the target tissue) and further, may permit thecompound(s) of formula (I) or (a) pharmaceutically acceptable salt(s)thereof to remain in contact with the target tissue for longer periodsof time. A suitable dosing regimen for intranasal compositions would befor the patient to inhale slowly through the nose subsequent to thenasal cavity being cleared. During inhalation the composition would beadministered to one nostril while the other is manually compressed. Thisprocedure may be repeated for the other nostril.

The suspending agent(s), if included, will typically be present in anamount of from 0.1 to 5% (w/w), such as from 1.5% to 2.4% (w/w), basedon the total weight of the composition. Examples of pharmaceuticallyacceptable suspending agents include, but are not limited to, Avicel®(microcrystalline cellulose and carboxymethylcellulose sodium),carboxymethylcellulose sodium, veegum, tragacanth, bentonite,methylcellulose, xanthan gum, carbopol and polyethylene glycols.

Compositions for administration to the lung or nose may contain one ormore excipients may be protected from microbial or fungal contaminationand growth by inclusion of one or more preservatives. Examples ofpharmaceutically acceptable anti-microbial agents or preservativesinclude, but are not limited to, quaternary ammonium compounds (forexample benzalkonium chloride, benzethonium chloride, cetrimide,cetylpyridinium chloride, lauralkonium chloride and myristyl picoliniumchloride), mercurial agents (for example phenylmercuric nitrate,phenylmercuric acetate and thimerosal), alcoholic agents (for examplechlorobutanol, phenylethyl alcohol and benzyl alcohol), antibacterialesters (for example esters of para-hydroxybenzoic acid), chelatingagents such as disodium edetate (EDTA) and other anti-microbial agentssuch as chlorhexidine, chlorocresol, sorbic acid and its salts (such aspotassium sorbate) and polymyxin. Examples of pharmaceuticallyacceptable anti-fungal agents or preservatives include, but are notlimited to, sodium benzoate, sorbic acid, sodium propionate,methylparaben, ethylparaben, propylparaben and butylparaben. Thepreservative(s), if included, may be present in an amount of from 0.001to 1% (w/w), such as from 0.015% to 0.5% (w/w) based on the total weightof the composition.

Compositions (for example wherein at least one compound is insuspension) may include one or more surfactants which functions tofacilitate dissolution of the medicament particles in the aqueous phaseof the composition. For example, the amount of surfactant used is anamount which will not cause foaming during mixing. Examples ofpharmaceutically acceptable surfactants include fatty alcohols, estersand ethers, such as polyoxyethylene (20) sorbitan monooleate(Polysorbate 80), macrogol ethers, and poloxamers. The surfactant may bepresent in an amount of between about 0.01 to 10% (w/w), such as from0.01 to 0.75% (w/w), for example about 0.5% (w/w), based on the totalweight of the composition.

One or more tonicity-adjusting agent(s) may be included to achievetonicity with body fluids e.g. fluids of the nasal cavity, resulting inreduced levels of irritancy. Examples of pharmaceutically acceptabletonicity-adjusting agents include, but are not limited to, sodiumchloride, dextrose, xylitol, calcium chloride, glucose, glycerine andsorbitol. A tonicity-adjusting agent, if present, may be included in anamount of from 0.1 to 10% (w/w), such as from 4.5 to 5.5% (w/w), forexample about 5.0% (w/w), based on the total weight of the composition.

The compositions of the invention may be buffered by the addition ofsuitable buffering agents such as sodium citrate, citric acid,trometamol, phosphates such as disodium phosphate (for example thedodecahydrate, heptahydrate, dihydrate and anhydrous forms), or sodiumphosphate and mixtures thereof.

A buffering agent, if present, may be included in an amount of from 0.1to 5% (w/w), for example 1 to 3% (w/w) based on the total weight of thecomposition.

Examples of taste-masking agents include sucralose, sucrose, saccharinor a salt thereof, fructose, dextrose, glycerol, corn syrup, aspartame,acesulfame-K, xylitol, sorbitol, erythritol, ammonium glycyrrhizinate,thaumatin, neotame, mannitol, menthol, eucalyptus oil, camphor, anatural flavouring agent, an artificial flavouring agent, andcombinations thereof.

One or more co-solvent(s) may be included to aid solubility of themedicament compound(s) and/or other excipients. Examples ofpharmaceutically acceptable co-solvents include, but are not limited to,propylene glycol, dipropylene glycol, ethylene glycol, glycerol,ethanol, polyethylene glycols (for example PEG300 or PEG400), andmethanol. In one embodiment, the co-solvent is propylene glycol.

Co-solvent(s), if present, may be included in an amount of from 0.05 to30% (w/w), such as from 1 to 25% (w/w), for example from 1 to 10% (w/w)based on the total weight of the composition.

Compositions for inhaled administration include aqueous, organic oraqueous/organic mixtures, dry powder or crystalline compositionsadministered to the respiratory tract by pressurised pump or inhaler,for example, reservoir dry powder inhalers, unit-dose dry powderinhalers, pre-metered multi-dose dry powder inhalers, nasal inhalers,nebulisers, or insufflators. Suitable compositions contain water as thediluent or carrier for this purpose and may be provided withconventional excipients such as buffering agents, tonicity modifyingagents and the like. Aqueous compositions may also be administered tothe nose and other regions of the respiratory tract by nebulisation.Such compositions may be aqueous solutions or suspensions.

Compositions for administration topically to the nose or to the lunginclude aqueous compositions delivered to the nasal cavities bypressurised pump. Suitable compositions contain water as the diluent orcarrier for this purpose. Aqueous compositions for administration to thelung or nose may be provided with conventional excipients such asbuffering agents, tonicity-modifying agents and the like. Aqueouscompositions may also be administered to the nose by nebulisation.

A fluid dispenser may typically be used to deliver a fluid compositionto the nasal cavities. The fluid composition may be aqueous ornon-aqueous, but typically aqueous. Such a fluid dispenser may have adispensing nozzle or dispensing orifice through which a metered dose ofthe fluid composition is dispensed upon the application of auser-applied force to a pump mechanism of the fluid dispenser. Suchfluid dispensers are generally provided with a reservoir of multiplemetered doses of the fluid composition, the doses being dispensable uponsequential pump actuations. The dispensing nozzle or orifice may beconfigured for insertion into the nostrils of the user for spraydispensing of the fluid composition into the nasal cavity. A fluiddispenser of the aforementioned type is described and illustrated inInternational Patent Application publication number WO 2005/044354(Glaxo Group Limited). The dispenser has a housing which houses afluid-discharge device having a compression pump mounted on a containerfor containing a fluid composition. The housing has at least onefinger-operable side lever which is movable inwardly with respect to thehousing to move the container upwardly in the housing by means of a camto cause the pump to compress and pump a metered dose of the compositionout of a pump stem through a nasal nozzle of the housing. In oneembodiment, the fluid dispenser is of the general type illustrated inFIGS. 30-40 of WO 2005/044354.

Aqueous compositions containing a compound of formula (I) or apharmaceutically acceptable salt thereof may also be delivered by a pumpas disclosed in International Patent Application publication number WO2007/138084 (Glaxo Group Limited), for example as disclosed withreference to FIGS. 22-46 thereof.

Dry powder compositions for topical delivery to the lung by inhalationmay, for example, be presented in capsules and cartridges of for examplegelatine, or blisters of for example laminated aluminium foil, for usein an inhaler or insufflator. Powder blend compositions generallycontain a powder mix for inhalation of the compound of formula (I) or apharmaceutically acceptable salt thereof and a suitable powder base(carrier/diluent/excipient substance) such as mono-, di-, orpolysaccharides (for example lactose or starch). Dry powder compositionsmay also include, in addition to the drug and carrier, a furtherexcipient (for example a ternary agent such as a sugar ester for examplecellobiose octaacetate, calcium stearate, or magnesium stearate.

In one embodiment, a composition suitable for inhaled administration maybe incorporated into a plurality of sealed dose containers provided onmedicament pack(s) mounted inside a suitable inhalation device. Thecontainers may be rupturable, peelable, or otherwise openableone-at-a-time and the doses of the dry powder composition administeredby inhalation on a mouthpiece of the inhalation device, as known in theart. The medicament pack may take a number of different forms, forinstance a disk-shape or an elongate strip. Representative inhalationdevices are the DISKHALER™ and DISKUS™ devices, marketed byGlaxoSmithKline.

A dry powder inhalable composition may also be provided as a bulkreservoir in an inhalation device, the device then being provided with ametering mechanism for metering a dose of the composition from thereservoir to an inhalation channel where the metered dose is able to beinhaled by a patient inhaling at a mouthpiece of the device. Exemplarymarketed devices of this type are TURBUHALER™ (AstraZeneca), TWISTHALER™(Schering) and CLICKHALER™ (Innovate.)

A further delivery method for a dry powder inhalable composition is formetered doses of the composition to be provided in capsules (one doseper capsule) which are then loaded into an inhalation device, typicallyby the patient on demand. The device has means to rupture, pierce orotherwise open the capsule so that the dose is able to be entrained intothe patient's lung when they inhale at the device mouthpiece. Asmarketed examples of such devices there may be mentioned ROTAHALER™(GlaxoSmithKline) and HANDIHALER™ (Boehringer Ingelheim.)

For administration by the intranasal route, a suitable metering means isa pump providing a pre-set amount of the pharmaceutical dosage form peractuation, for example 50 microlitres per actuation or 100 microlitresper actuation.

A suitable pump is a Valois VP7 spray pump (Valois Pharm, Route desFalaises, 27100 Le Vaudreuil, France).

A suitable pharmaceutical composition for intranasal administrationcomprising Compound (I), or a pharmaceutically acceptable salt thereof,which is suitable for use with a metering means is a suspension orsolution, for example an aqueous solution. The pharmaceuticalcomposition may contain from 0.01 to 1000 microgrammes of Compound (I)per millilitre, for example 0.01 microgrammes to 100 microgrammes ofCompound (I) per millilitre.

The pharmaceutical composition for intranasal administration comprisingCompound (I), or a pharmaceutically acceptable salt thereof, suitablefor use with a metering means, may be held in any container suitable forthe containment and storage of the composition, which container isadapted to receive the metering means, for example a Type 1 amber glassbottle (available, for example, from Saint Gobain Desjonquères (SGD),Avenue Pierre et Marie Curie, Mers-les-Bains, Picardie, France, 80350.)

For intranasal administration, the composition of the invention may beadministered once per week, for example one actuation of the meteringmeans to each nostril per week, for 6 weeks.

The components other than Compound (I), or a pharmaceutically acceptablesalt thereof, used to prepare these compositions are commerciallyavailable, for example Sodium Chloride Ph. Eur. or USP (e.g. MortonSalt, 123 N. Wacker Drive, Chicago, Ill., 60606, US), BenzalkoniumChloride Solution Ph. Eur. or USP (e.g. Merck Chemicals LTD., BoulevardIndustrial Park, Padge Road, Beeston, Nottingham NG9 2JR, UK), DisodiumEdetate Ph. Eur. or USP (e.g. Dow Chemical Co, Seal Sands,Middlesbrough, Cleveland, TS2 1UD, UK).

For the avoidance of doubt, when reference is made herein to scalaramounts, including microgramme amounts, nanogramme amounts and % weightamounts, of ‘Compound (I), or a pharmaceutically acceptable saltthereof’, the scalar amount referred to is made in respect of Compound(I) per se. For example, 1.3 nanogrammes of Compound (I) in the form ofthe 1:1 maleate salt is that amount of maleate salt which contains 1nanogramme of Compound (I).

Compound (I) exists in tautomeric forms. It will be understood that thepresent invention encompasses all of the tautomers of Compound (I)whether as individual tautomers or as mixtures thereof.

Compound (I) or a pharmaceutically acceptable salt thereof, may beprepared using known methods, for example those disclosed in WO2010/018133.

A maleate salt of Compound (I) may be prepared from Compound (I) byreacting6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-onewith maleic acid, in a suitable solvent to produce6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-onein the form of a maleate salt. In one aspect, the process produces a 1:1ratio of maleic acid:6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one.

The pharmaceutical compositions of the invention may be prepared andformulated according to conventional methods such as those disclosed inthe British, European, and United States Pharmacopoeias, Remington'sPharmaceutical Sciences (Mack Publishing Co.), Martindale The ExtraPharmacopoeia (London, The Pharmaceutical Press), and Harry'sCosmeticology (Leonard Hill Books).

The pharmaceutical compositions for intranasal administration aretypically prepared from a concentrated solution by serial dilution. Thecomponents of the formulation are dissolved in purified water and mixedto provide a concentrated solution of Compound (I) or a pharmaceuticallyacceptable salt thereof, for example 100 microgrammes per millilitre. Aplacebo solution is also prepared in a similar manner to theconcentrated solution, but without Compound (I) or a pharmaceuticallyacceptable salt thereof. The concentrated solution is diluted with theplacebo solution to provide formulations of the desired concentration.Examples of the preparation of solutions containing the maleate salt ofCompound (I) and a placebo solution are provided in FIGS. 1-3.

Preparation of Compound (I), maleate salt

Reference Example 16-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinl)pentyl]-7,9-dihydro-8H-purin-8-one,maleate salt

Preparation 1

6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one(for example, as prepared for Reference Example 1) (0.384 g, 0.98 mmol)was dissolved in isopropyl alcohol (4.6 mL, 12 vols) and heated to 40°C. Maleic acid (0.114 g, 0.98 mmol) was added. A clear solution wasobtained. During cooling to room temperature, precipitation occurred.The slurry was filtered, washed with iso-propyl alcohol (5 mL) and driedunder reduced pressure at 40° C. to constant weight.6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one, maleate salt (0.305 g, 61% th) wasobtained as a white solid.

¹H NMR confirms a 1:1 ratio of maleic acid:6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one. ¹H NMR (400 MHz, DMSO-d₆) δ ppm,9.85 (1H, s, (CH₂)₃NHCO), 8.85 (1H, br s, NH⁺), 6.39 (2H, s, NH₂), 6.02(2H, s, HO₂C(CH)₂), 5.00 (1H, m, J=6.2 Hz, CH₃CH), 3.68 (2H, t, J=6.8,Hz NCH₂), 3.40 (2H, m, NCH₂), 2.98 (2H, m, J=8.1 Hz NCH₂), 2.82 (2H, brs, NCH₂), 1.85-1.24 (16H, m, 8×CH₂), 1.21 (3H, d, J=6.1 Hz, CHCH₃), 0.89(3H, t, J=7.3 Hz, CH₂CH₃), 2.5 (solvent (DMSO)).

Preparation 2

A solution of 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (for example, as prepared forReference Example 1) (1.46 g, 3.74 mmol) in iso-propyl alcohol (14.6 mL,10 vols) was clarified (filtered at room temperature through a BondElutcartridge) and then heated to approximately 50° C. A solution of maleicacid (0.434 g, 3.74 mmol) in isopropyl alcohol (2.9 mL, 2 vols) wasadded. The resulting solution was then seeded and cooled to 45° C.Further seed was added. The resulting slurry was cooled to roomtemperature and held overnight (approximately 16 hours), then cooled inan ice/water bath for 30 minutes. The slurry was filtered, washing withiso-propyl alcohol (4.5 mL, 3 vols and then 3 mL, 2 vols). The productwas dried under reduced pressure at 40° C. to constant weight to give6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one, maleate salt (1.305 g, 69% th).

Reference Example 26-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one,maleate salt

A solution of 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (398 g, 1.02 mol) in iso-propylalcohol (3.59 L, 10 vols) was clarified (filtered at room temperaturethrough a 5 micron in-line filter) and then heated to 50° C. A solutionof maleic acid (118 g, 1.02 mol) in iso-propyl alcohol (997 mL, 2 vols)was added. The resulting solution was then seeded (1.2 g, 3 mmol) andcooled to 40-45° C. and aged for 30 minutes. The resulting slurry wascooled to 10° C. over 1.5 hours, held for 30 minutes and then filtered,washing with iso propyl alcohol (1.20 L, 3 vols). The product was driedunder reduced pressure at 40° C. to constant weight to give6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one, maleate salt (296 g, 57% th).

The following examples illustrate the invention but do not limit it inany way.

EXAMPLES Example 1

Composition of Nasal Spray Solution containing Compound (I) at 0.01mg/mL, 0.1 mg/mL and 1 ml/mL

Active ingredient Other components Compound Sodium Benzalkonium DisodiumPurified Quantity Concentration (I)² chloride Chloride³ Edetate WaterPer 0.01 μg/mL Bottle Compound (I) μg/mL 0.013 9000 300 150 To 100 % w/w0.0000013 0.90 0.03 0.015 Per spray¹ (100 μL pump) μg 0.0013⁴ 900 30 15To 100 Per 0.1 μg/mL Bottle Compound (I) μg/mL 0.13 9000 300 150 To 100% w/w 0.000013 0.90 0.03 0.015 Per spray¹ (100 μL pump) μg 0.013⁵ 900 3015 To 100 Per 1 μg/mL Bottle Compound (I) μg/mL 1.3 9000 300 150 To 100% w/w 0.00013 0.90 0.03 0.015 Per spray¹ (50 μL pump) μg 0.065 450 157.5 To 50 (100 μL pump) μg 0.13⁶ 900 30 15 To 100 Function ActiveTonicity Preservative Preservative Vehicle agent Reference to StandardUSP or USP or USP or USP or Ph. Eur. Ph. Eur. Ph. Eur. Ph. Eur. Note:¹Theoretical quantity per spray (ex-device) ²The quantity of Compound(I) may be adjusted to reflect the assigned purity of the input drugsubstance (Compound (I) as 1:1 maleate salt). Salt to base factor is 1.3³Aqueous solution containing 50% benzalkonium chloride ⁴Equates to 1 ngCompound (I) ⁵Equates to 10 ng Compound (I) ⁶Equates to 100 ng Compound(I)

Example 2

Composition of Nasal Spray Solution containing Compound (I) at 10 mg/mL

Active ingredient Other components Compound Sodium Benzalkonium DisodiumPurified Quantity Concentration (I)² chloride Chloride³ Edetate WaterPer 10 μg/mL Bottle Compound (I) μg/mL 13 9000 300 150 To 100 % w/w0.0013 0.90 0.03 0.015 Per spray¹ (50 μL pump) μg 0.65⁴ 450 15 7.5 To 50(100 μL pump) μg 1.3⁵ 900 30 15 To 100 Function Active TonicityPreservative Preservative Vehicle agent Reference to Standard USP or USPor USP or USP or Ph. Eur. Ph. Eur. Ph. Eur. Ph. Eur. Note: ¹Theoreticalquantity per spray (ex-device) ²The quantity of Compound (I) may beadjusted to reflect the assigned purity of the input drug substance(Compound (I) as 1:1 maleate salt). Salt to base factor is 1.3 ³Aqueoussolution containing 50% benzalkonium chloride ⁴Equates to 500 ngCompound (I) ⁵Equates to 1000 ng Compound (I)

Example 3

Composition of Nasal Spray Solution containing Compound (I) at 100 mg/mL

Active ingredient Other components Compound Sodium Benzalkonium DisodiumPurified Quantity Concentration (I)² chloride Chloride³ Edetate WaterPer 100 μg/mL Bottle Compound (I) μg/mL 130 9000 300 150 To 100 % w/w 0.013 0.90 0.03 0.015 Per spray¹ (50 μL pump) μg  6.5⁴ 450 15 7.5 To 50(100 μL pump) μg  13⁵ 900 30 15 To 100 Function Active TonicityPreservative Preservative Vehicle agent Reference to Standard USP or USPor USP or USP or Ph. Eur. Ph. Eur. Ph. Eur. Ph. Eur. Note: ¹Theoreticalquantity per spray (ex-device) ²The quantity of Compound (I) may beadjusted to reflect the assigned purity of the input drug substance(Compound (I) as 1:1 maleate salt). Salt to base factor is 1.3 ³Aqueoussolution containing 50% benzalkonium chloride ⁴Equates to 5000 ngCompound (I) ⁵Equates to 10000 ng Compound (I)

1. A pharmaceutical dosage form comprising Compound (I):

or a pharmaceutically acceptable salt thereof, and means for providing ametered-dose of Compound (I), or a pharmaceutically acceptable saltthereof.
 2. A pharmaceutical dosage form according to claim 1, whichprovides 0.5 nanogramme to 20 microgrammes of Compound (I) per actuationof the metering means.
 3. A pharmaceutical dosage form according toclaim 1 which provides 0.5 nanogramme to 5 microgrammes per actuation ofthe metering means.
 4. A pharmaceutical dosage form according to claim 1which provides 1 nanogramme to 5 microgrammes per actuation of themetering means.
 5. A pharmaceutical dosage form according to claim 1which provides 0.5 nanogramme to 999 nanogrammes per actuation of themetering means.
 6. A pharmaceutical dosage form according to claim 1which provides 1 nanogramme to 999 nanogrammes per actuation of themetering means.
 7. A pharmaceutical composition comprising Compound (I):

or a pharmaceutically acceptable salt thereof, characterised in that thepharmaceutical composition is suitable for use with metering means.
 8. Amethod of treatment of allergic diseases and other inflammatoryconditions, for example allergic rhinitis and allergic asthma, whichmethod comprises the administration of Compound (I):

or a pharmaceutically acceptable salt thereof, in an amount equivalentto 0.5 nanogramme to 40000 nanogrammes of Compound (I) to a human inneed thereof.
 9. A method of treatment according to claim 8, whichcomprises the administration of 1 nanogramme to 20000 nanogrammes ofCompound (I) to a human in need thereof.
 10. A method of treatmentaccording to claim 8, which comprises the administration of 2nanogrammes to 20000 nanogrammes of Compound (I) to a human in needthereof.
 11. A method of treatment according to claim 8, which comprisesthe administration of 1 nanogramme to 4000 nanogrammes of Compound (I)to a human in need thereof.
 12. A method of treatment according to claim8, which comprises the administration of 2 nanogrammes to 4000nanogrammes of Compound (I) to a human in need thereof.
 13. A method oftreatment according to claim 8, which comprises the administration of 1nanogramme to 999 nanogrammes of Compound (I) to a human in needthereof.
 14. A method of treatment according to claim 8, which comprisesthe administration of 2 nanogrammes to 999 nanogrammes, of Compound (I)to a human in need thereof.
 15. A method of treatment according to claim8, wherein the administration takes place once per week. 16-23.(canceled)